The Clinic a l Problem
A 30-year-old woman presents with a history of no menses since she stopped taking oral contraceptives 6 months ago in order to conceive. She had undergone puberty that was normal in both timing and development, with menarche at 12 years of age. At 18 years of age, she started taking oral contraceptives for irregular menses. She reports stress at work. Her weight is 59 kg, and her height 1.66 m; her body-mass index (the weight in kilograms divided by the square of the height in meters) is 21.3. There is no galactorrhea, hirsutism, or acne. The pelvic examination is normal, a pregnancy test is negative, the prolactin level is normal, and the follicle-stimulating hormone (FSH) level is in the menopausal range. How should she be evaluated and treated?
The Clinic a l Problem
The ovary is unique in the endocrine system in that an entirely new secretory struc ture is developed within it each month -the graafian follicle, which arises from a microscopic primordial follicle. Menopause, defined as the permanent cessation of menses, results from the depletion of potentially functional primordial follicles. The mean (±SD) age at the time of natural menopause is 50±4 years. 1 Menopause before the age of 40 years is considered to be premature.
Primary ovarian insufficiency is the preferred term for the condition that was previously referred to as premature menopause or premature ovarian failure; other terms used for this condition include primary ovarian failure and hypergonadotro pic hypogonadism, as well as the misnomer, gonadal dysgenesis. 2, 3 The condition is considered to be present when a woman who is less than 40 years old has had amenorrhea for 4 months or more, with two serum FSH levels (obtained at least 1 month apart) in the menopausal range. 4, 5 The condition differs from menopause in that there is varying and unpredictable ovarian function in approximately 50% of cases, and about 5 to 10% of women conceive and deliver a child after they have received the diagnosis. 4,6-9 Thus, the term "primary ovarian insufficiency," as originally suggested by Albright, meets the need to describe a continuum of im paired ovarian function rather than a dichotomous state. 2, 3 This term may also be less stigmatizing than the terms that were used previously.
In 90% of the cases of primary ovarian insufficiency, the cause remains a mystery. Spontaneous 46,XX primary ovarian insufficiency can occasionally occur as part of a syndrome (Table 1 ). In addition, several single genes (e.g., bone morphoge netic protein 15 [BMP15] , diaphanous homolog 2 [DIAPH2], and inhibin alpha sub unit [INHA] ) have been associated with nonsyndromic primary ovarian insufficiency, but their clinical relevance is not clear. Structural abnormalities in the X chromo some apart from specific gene mutations may also be a cause.
Primary ovarian insufficiency occurs through two major mechanisms: follicle dysfunction and follicle depletion. 5 Follicle dysfunction indicates that follicles remain in the ovary, but a pathologic process prevents This review focuses on spontaneous 46,XX their normal function (e.g., as a result of an primary ovarian insufficiency, which affects ap FSH-receptor mutation). 10 Follicle depletion indi proximately 1 in 100 women by the time they are cates that no primordial follicles remain in the 40 years of age. 13 ovary. This condition may be due to the failure of an adequate initial pool of primordial follicles S tr ategies a nd Ev idence to be established in utero, an accelerated expen diture of follicles, or autoimmune or toxic de-Evaluation struction of follicles. luteinized, a major mechanism of follicle dysfunction in these women
Ovarian follicle depletion
Insufficient initial follicle number Blepharophimosis, ptosis, epicanthus inversus syndrome
Mutation in FOXL2 is a mechanism of familial primary ovarian insufficiency, and disruption of the mouse gene causes a pervasive block in primor dial follicle development; rare disorder
Spontaneous accelerated follicle loss
Turner's syndrome Although a normal complement of primordial follicles is established in the ovary during fetal development, follicle loss through apoptosis is accelerated so that the store of primordial follicles is typically depleted before puberty; in oocytes, both X chromosomes must be present and remain active to prevent accelerated follicular atresia; the individual genes responsible for this ovarian syndrome have not been identified Environmental-toxin-induced follicle loss Industrial exposure to 2-bromopropane Exposure to cleaning solvent associated with primary ovarian insufficiency
in 16 Korean women
T h e ne w e ngl a nd jou r na l o f m e dic i ne condition develops after a normal puberty and tion the earliest manifestation of a decline in established regular menses, although primary general health, such as uncontrolled diabetes amenorrhea may be the presenting feature in mellitus, or of an underlying condition, such as about 10% of cases. 4 Occasionally, menses stop celiac disease? 14, 15 Is it related to excessive exer abruptly. In some women, menses fail to resume cise, inadequate caloric intake, or emotional after a pregnancy or after they have stopped tak stress? Has the woman undergone prior radia ing hormonal contraceptives. Most commonly, tion therapy or chemotherapy? Is there galactor there is a prodrome of oligomenorrhea, polymen rhea (suggestive of hyperprolactinemia) or are orrhea, or dysfunctional uterine bleeding. there signs of androgen excess? Although the list Once pregnancy has been ruled out, clinicians of potential causes of secondary amenorrhea is evaluating women with secondary amenorrhea long, the majority of cases are accounted for by should address several questions: Is this condi four conditions: the polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and primary ovarian insufficiency. 14 It is inappro priate to attribute amenorrhea to stress without further evaluation.
Diagnostic criteria have not been established by any professional organization. A commonly used definition requires that there be at least 4 months of amenorrhea. 4, 16 However, because approximately 50% of women with primary ovar ian insufficiency have intermittent ovarian func tion leading to intermittent and unpredictable menses, rather than complete amenorrhea, a more practical definition is 4 months or more of "dis ordered" menses (amenorrhea, oligomenorrhea, polymenorrhea, or metrorrhagia) in association with menopausal FSH levels.
Symptoms of estrogen deficiency develop in many, but not all, patients. These symptoms in clude vasomotor symptoms (hot flashes and night sweats), sleep disturbance, and dyspareunia re lated to vaginal dryness. However, not all patients have profound estrogen deficiency, and a vaginal examination often shows effects suggesting nor mal estrogen levels.
Although most cases of primary ovarian in sufficiency occur sporadically, there is a positive family history, with an affected first-degree rela tive, in approximately 10 to 15% of cases. 17 Thus, patients should be queried about family history as well as about other autoimmune disorders (including hypothyroidism, adrenal insufficiency, and hypoparathyroidism) that might relate to an autoimmune polyglandular syndrome. The con dition may also be associated with the dry-eye syndrome, myasthenia gravis, rheumatoid arthri tis, or systemic lupus erythematosus. 18, 19 A fam ily history of the fragile X syndrome, intellectual disability, dementia, tremor or ataxia, or symp toms similar to those associated with Parkinson's disease might point to a premutation in the frag ile X mental retardation 1 (FMR1) gene. 20 The physical examination may reveal evidence of an associated disorder such as hyperpigmenta tion or vitiligo (which is associated with autoim mune adrenal insufficiency), thyroid enlargement, or stigmata indicative of Turner's syndrome, such as short stature, webbed neck, and high, arched palate.
After pregnancy is ruled out, the initial evalu ation of amenorrhea should include, at a mini mum, the measurement of serum prolactin, FSH, and thyrotropin levels. 14 In cases of amenorrhea caused by stress (i.e., hypothalamic amenorrhea), the serum FSH level is in the low or normal range. If the FSH level is in the menopausal range, as defined by the reporting laboratory, the test should be repeated in 1 month along with a serum estradiol measurement. A progestinwithdrawal test (in which a progestin is admin istered and then withdrawn in order to determine whether vaginal bleeding ensues after its with drawal) was previously used as a diagnostic test of ovarian function, but it is not currently recom mended. Nearly 50% of women with primary ovarian insufficiency have withdrawal bleeding in response to the test, despite the presence of menopausal-level gonadotropins, and in the case of these women, relying on this bioassay would delay the diagnosis. 4 In cases of primary ovarian insufficiency that are not associated with a syndrome, the labora tory tests that are recommended to determine the cause include a karyotype analysis and testing for an FMR1 premutation and for adrenal anti bodies (with the use of indirect immunofluores cence or 21-hydroxylase [CYP21] immunoprecipi tation); pelvic ultrasonography should also be performed. Approximately 2% of women with isolated spontaneous 46,XX primary ovarian in sufficiency and 14% with familial spontaneous 46,XX primary ovarian insufficiency have an FMR1 premutation, which confers a risk of hav ing a child with fragile X syndrome. 20 The results of adrenal antibody testing are positive in ap proximately 4% of women with primary ovarian insufficiency. These women have steroidogenic cell autoimmunity, and lymphocytic autoimmune oophoritis is the mechanism of the ovarian insuf ficiency (Fig. 1) . Ovarian antibodies lack speci ficity, and testing for them is not warranted. 21 Pelvic ultrasonography identifies cases involving enlarged, multifollicular ovaries, which may un dergo torsion, such as in isolated 17,20-lyase de ficiency or autoimmune oophoritis (Table 2 ). An ovarian biopsy does not provide information that is helpful in the management of primary ovarian insufficiency and is therefore not indicated; preg nancy may occur even after examination of a biopsy specimen has shown that follicles are absent. 6 
Management
The diagnosis of primary ovarian insufficiency affects a woman's physical and emotional well-being, and the management of the condition should address both. Other associated endocrine deficiencies, as well as anxiety, depression, or both, may develop. The presence of an abnormal karyotype, an iatrogenic cause, or a premutation in the FMR1 gene has additional health implica tions that are beyond the scope of this article. The ovary appears normal, with the presence of multi ple follicles, despite amenorrhea, estrogen deficiency, and menopausal-level gonadotropins. Autoimmune oophoritis with thecal infiltration by lymphocytes was confirmed histologically by means of an ovarian biopsy performed when the patient was 26 years of age. 9 
Emotional Health
Unexpected infertility is a life-altering diagnosis for many women. 22 Shyness and social anxiety, impaired self-esteem, and a perceived low level of social support are more frequent among women with spontaneous 46,XX primary ovarian insuf ficiency than among women who do not have this condition. 23, 24 Many women report experiencing severe emotional distress 25 and want guidance on how to cope with the emotional sequelae, but few ask for it directly. It is best to schedule a re turn office visit to inform women of this diagno sis; patients should be encouraged to identify sources of emotional support. 24 
Hormone-Replacement Therapy
Early menopause has been associated with an in creased incidence of fractures 26 and increased total mortality and mortality due to ischemic heart disease. [27] [28] [29] In a study of women who were part of the Women's Health Initiative, combined hormone-replacement therapy (estrogen with pro gestin) increased the risk of cardiovascular events; however, it is invalid to apply the results of this study, which involved menopausal women who were, on average, 63 years of age, 30 to young women with primary ovarian insufficiency. (Meno pause is a physiologic condition, whereas prima ry ovarian insufficiency is a pathologic condition in which women have low serum estradiol levels as compared with other women of similar age.) Although data from randomized, controlled trials are lacking, most experts agree that physiologic estrogen and progestin replacement is reasonable in the case of young women with primary ovarian insufficiency and should be continued until they reach the age when menopause usually occurs. 3 The average serum estradiol level during the menstrual cycle in women with a normal men strual history is approximately 100 pg per millili ter. 31 Although no studies have directly compared various hormonal therapies for women with pri mary ovarian insufficiency, a dose of 100 μg of estradiol per day, administered by transdermal patch, achieves average serum estradiol levels in this range and effectively treats symptoms. Trans dermal estradiol has little effect on hemostatic factors, and in case-control studies, it has been associated with a lower risk of venous thrombo embolism than has oral estrogen. [32] [33] [34] Evidence supports the use of cyclic medroxyprogesterone acetate at a dose of 10 mg per day for 12 days each month as the preferred progestin. This regi men fully induces secretory endometrium and provides protection against endometrial cancer. 35, 36 Data regarding the effects on the endometrium of oral micronized progesterone when it is given in conjunction with a full replacement dose of estrogen are not available. 37 Patients should keep a menstrual calendar and take a pregnancy test if a menstrual period is late. Pregnancy may oc cur while a woman is taking estrogen and pro gestin therapy, and the therapy should be stopped if the pregnancy test is found to be positive. Oral contraceptives provide more steroid hormone than is needed for physiologic replacement and are therefore not recommended as first-line man agement.
Maintaining Bone Health
Women with primary ovarian insufficiency have reduced bone mineral density as compared with controls. 38 Thus, bone mineral density should be measured, and women should be educated regard ing strategies to maintain bone health. No data are available specifically for these women with regard to the recommended daily intake of cal cium and of vitamin D and the recommended frequency and intensity of weight-bearing exer cise, but it seems reasonable to follow the guide lines developed for perimenopausal and post menopausal women by the North American Menopause Society: intake of 1200 mg of elemen tal calcium per day and maintenance of adequate vitamin D status, which is defined as a serum 25-hydroxyvitamin D level of 30 ng per milliliter (75 nmol per liter) or higher. 39 Vitamin D defi ciency is common, and it has been recommended that adults with inadequate exposure to the sun take at least 800 to 1000 IU of vitamin D 3 per day. 40 Women should be encouraged to engage in a variety of exercises, such as jogging, walking, and stair climbing, along with resistance exercis es. 41 Bisphosphonates are not advised if preg nancy is possible, since these agents have long skeletal half-lives and the effects on the fetus are uncertain. 42 
Associated Disorders
There is a 50% risk of the development of adrenal insufficiency in women with adrenal autoimmu nity. 43 Patients with positive tests for adrenal anti bodies should be evaluated annually with the use of a corticotropin stimulation test. Longitudinal data are lacking to guide the optimal follow-up for patients with negative tests for adrenal anti bodies at the initial examination. Theoretically, one would expect adrenal-cell antibodies to be present when the ovarian insufficiency develops if the mechanism is steroidogenic cell autoimmu nity. If both tests for adrenal autoimmunity, as measured by indirect immunofluorescence and 21-hydroxylase immunoprecipitation, are negative at the initial examination, a reasonable strategy is not to repeat the testing unless it is otherwise clinically indicated. However, all patients with primary ovarian insufficiency should be educated regarding the symptoms of adrenal insufficiency and should undergo evaluation of adrenal func tion if such symptoms develop.
There is an increased incidence of the dry-eye syndrome and ocular-surface disease in women with primary ovarian insufficiency, as compared with controls (20% vs. 3%), and women who have either of these disorders benefit from referral to an ophthalmologist. 18 Thyroid autoimmune dis ease, most commonly Hashimoto's thyroiditis, is present in 14 to 27% of women 19, 44 at initial diag nosis. It is reasonable to measure thyrotropin levels and test for the presence of thyroid per oxidase antibodies. Other autoimmune disorders, such as myasthenia gravis, rheumatoid arthritis, and systemic lupus erythematosus, have also been reported in association with primary ovarian in sufficiency, 19 but such cases are infrequent, and testing for these and other autoimmune condi tions should be predicated on symptoms and signs that are suggestive of the condition.
Family Planning
Patients who wish to avoid pregnancy should use a barrier method or possibly an intrauterine de vice. The effectiveness of oral contraceptives has not been studied in women with primary ovarian insufficiency, and there are anecdotal reports of women who have conceived while complying with the oral contraceptive regimen, 45 perhaps be cause of a failure of the oral contraceptive to sup press the high FSH levels that are characteristic of this condition.
Patients should understand that spontaneous remission resulting in pregnancy occurs in 5 to 10% of cases. 8 Generally, remissions are tempo rary, but they may (although rarely) last for years. 5 Currently, there are no known markers that are associated with an increased rate of remission, and there are no therapies that have been shown to restore ovarian function and fertility. Some couples are averse to adoption and to reproduc tive technologies and are content not to become parents or to accept the low but real chance that the infertility will resolve spontaneously. For cou ples who decide to pursue parenthood actively, the options are adoption, foster parenthood, egg donation, and embryo donation; ovarian trans plantation has been performed in rare cases in which the patient has an identical twin with nor mal ovarian function. 46 There is no medical ur gency to proceed to egg donation, because the rates of pregnancy with egg donation appear to be similar among older and younger women. 47 Women with primary ovarian insufficiency who become pregnant as a result of oocyte donation may have an increased risk of delivering infants who are small for gestational age and of having pregnancy-induced hypertension and postpartum hemorrhage, 48-50 but these findings are contro versial. 51 A r e a s of Uncerta int y Studies involving women with the FMR1 premu tation have established that this mechanism of primary ovarian insufficiency is associated with a clinical spectrum of impaired ovarian function that involves a continuum of occult, biochemical, and overt ovarian insufficiency; a better under standing is needed of the spectrum of disease associated with other causes of primary ovarian insufficiency (Table 3) . 3, [52] [53] [54] In addition, research is needed on strategies to improve fertility for women who have follicles remaining in the ovary. The magnitude of long-term risks associated with the disorder (including cardiovascular disease and osteoporosis) and the optimal means of re ducing these risks are uncertain.
Guidelines
Several professional organizations recommend that women with primary ovarian insufficiency undergo testing for a premutation in the FMR1 gene. [55] [56] [57] The American Society for Reproductive Medicine and the International Menopause Soci ety recommend estrogen-replacement therapy for women with primary ovarian insufficiency. 14, 58 Conclusions a nd R ecommendations
The woman in the vignette has amenorrhea and a menopausal FSH level. Confirmation of the ele vated FSH level and a low estradiol level would confirm the diagnosis of primary ovarian insuf ficiency. This information is highly emotionally charged and should be discussed with the patient at a return visit to the office rather than by tele phone, with recognition of the emotional effect of the diagnosis. Patients should understand that remission may occur and that pregnancy, though unlikely, occurs in 5 to 10% of cases. A karyotype analysis, tests for the FMR1 premutation and ad renal autoimmunity, a pelvic ultrasound exami nation, and measurement of bone mineral density are indicated at the time of diagnosis. Women with primary ovarian insufficiency should be en couraged to maintain a lifestyle that optimizes bone and cardiovascular health, including engag ing in regular weight-bearing exercise, maintain ing an adequate intake of calcium (1200 mg daily) and vitamin D (at least 800 IU daily), eating a healthy diet to avoid obesity, and undergoing screening for cardiovascular risk factors, with treatment of any identified risk factors. Although there are no data from randomized trials to guide the use of hormonal therapy in women with this condition, a reasonable regimen would be 100 μg of transdermal estradiol and 10 mg of oral me droxyprogesterone acetate daily for the first 12 days of each month. Women should keep a men strual calendar and have a pregnancy test prompt ly in the case of late menses. Dr. Nelson reports being an inventor on three United States patents directed to MATER (a potential antigen in autoimmune primary ovarian insufficiency) and its applications (U.S. patent numbers 7,189,812; 7,217,811; and 7,432,067), as well as one pending United States patent application (U.S. patent applica tion number 11/586,160) and foreign counterparts. No other potential conflict of interest relevant to this article was re ported.
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